{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:06:25Z","timestamp":1788375985129,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cardiovascular risk factors and related disorders are common among older adults, and use of various classes of cardiovascular (CV) drugs could reduce the risk of cardiovascular disease (CVD). However, data are sparse with regard to the use of CV drugs among rural-dwelling older adults in China. Therefore, this population-based study aimed to describe use of CV drugs among older adults living in the rural communities in China, while taking into account the use of CV drugs for primary and secondary prevention of CVDs. This study included 5,246 participants (age \u226565 years; 57.17% women; 40.68% illiteracy) in the baseline examination of the MIND-China study. In March-September 2018, data on health-related factors, CVDs (ischemic heart disease, atrial fibrillation, heart failure, and stroke), and CV drug use were collected via face-to-face survey, clinical examination, and laboratory tests. We classified CV drugs according to the Anatomical Therapeutic Chemical classification system for western medications and specific cardiovascular effects for the products of traditional Chinese medicine (TCM). We conducted descriptive analysis. The overall prevalence of major cardiovascular risk factors ranged from 14.30% in diabetes and 23.81% in dyslipidemia to 66.70% in hypertension, and CVDs affected 35.07% of all participants (36.28% in women vs. 33.47% in men, <jats:italic>p<\/jats:italic> = 0.035). In the total sample, calcium channel blockers (C08) were most commonly used (10.39%), followed by TCM products (7.64%), hypoglycemic agents (A10, 4.73%), renin-angiotensin system (RAS)-acting agents (C09, 4.61%), and lipid-lowering agents (C10, 4.17%). The proportions of CV drugs for primary prevention (i.e., use of CV drugs among people without CVD) were 3.14% for antithrombotic agents (mainly aspirin), 1.38% for lipid-lowering agents, and 3.11% for RAS-acting agents; the corresponding figures for secondary prevention (i.e., use of CV drugs among people with CVD) were 13.97%, 9.35%, and 7.39%. In conclusion, despite highly prevalent cardiovascular risk factors and CVDs, a fairly low proportion of the rural-dwelling older adults take CV medications for primary and secondary prevention. Notably, TCM products are among the most commonly used CV drugs. These results call for additional efforts to promote implementation of the evidence-based recommendations for prevention of CVDs in the primary care settings.<\/jats:p>","DOI":"10.3389\/fphar.2020.608136","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T06:07:42Z","timestamp":1608271662000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":60,"title":["Use of Cardiovascular Drugs for Primary and Secondary Prevention of Cardiovascular Disease Among Rural-Dwelling Older Chinese Adults"],"prefix":"10.3389","volume":"11","author":[{"given":"Lin","family":"Cong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0210988","DOI":"10.1371\/journal.pone.0210988","article-title":"Effect of evidence-based therapy for secondary prevention of cardiovascular disease: systematic review and meta-analysis","volume":"14","author":"Aalto-Setala","year":"2019","journal-title":"PloS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc19-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e83822","DOI":"10.1371\/journal.pone.0083822","article-title":"China\u2019s rural public health system performance: a cross-sectional study","volume":"8","author":"Baradaran","year":"2013","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1136\/heartjnl-2016-309573","article-title":"Trends in the epidemiology of cardiovascular disease in the UK","volume":"102","author":"Bhatnagar","year":"2016","journal-title":"Heart"},{"key":"B7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijcard.2013.12.065","article-title":"Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5million people","volume":"172","author":"Chen","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ijcard.2014.09.201","article-title":"Patterns of cardiovascular drugs prescribed for an elderly Swedish population","volume":"177","author":"Ding","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1016\/j.jacc.2019.04.036","article-title":"Epidemiology of cardiovascular disease in China and opportunities for improvement","volume":"73","author":"Du","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3967\/bes2017.059","article-title":"Regional variations in medication usage for cardiovascular diseases at the community level in China (PURE-China study)","volume":"30","author":"Gang","year":"2017","journal-title":"Biomed. Environ. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/ageing\/afx158","article-title":"Medication usage change in older people (65+) in England over 20 years: findings from CFAS I and CFAS II","volume":"47","author":"Gao","year":"2018","journal-title":"Age Ageing"},{"key":"B12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cger.2005.09.011.x","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"22","author":"Garcia","year":"2006","journal-title":"Clin. Geriatr. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1001860","DOI":"10.1371\/journal.pmed.1001860","article-title":"The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study","volume":"12","author":"Gu","year":"2015","journal-title":"PLoS Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.jacc.2017.04.041","article-title":"Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms","volume":"69","author":"Hao","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD000011","DOI":"10.1002\/14651858.CD000011.pub3","article-title":"Interventions for enhancing medication adherence","volume":"2014","author":"Haynes","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1423-0127-18-30","article-title":"Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection","volume":"18","author":"Ho","year":"2011","journal-title":"J. Biomed. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.11909\/j.issn.1671-5411.2019.03.014","article-title":"2018 Chinese guidelines for prevention and treatment of hypertension-A report of the revision committee of Chinese guidelines for prevention and treatment of hypertension","volume":"16","year":"2019","journal-title":"J. Geriatr. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamacardio.2016.0218","article-title":"Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews","volume":"1","author":"Karmali","year":"2016","journal-title":"JAMA Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s0140-6736(15)00469-9","article-title":"Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data","volume":"387","author":"Khatib","year":"2016","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/alz.12123","article-title":"World\u2010Wide FINGERS Network: a global approach to risk reduction and prevention of dementia","volume":"16","author":"Kivipelto","year":"2020","journal-title":"Alzheimers Dement"},{"key":"B23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/pds.878","article-title":"A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohort","volume":"12","author":"Klarin","year":"2003","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamainternmed.2016.0190","article-title":"The burden of hypertension and associated risk for cardiovascular mortality in China","volume":"176","author":"Lewington","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/jamacardio.2019.0295","article-title":"Burden of cardiovascular diseases in China, 1990\u20132016","volume":"4","author":"Liu","year":"2019","journal-title":"JAMA Cardiology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(08)61362-8","article-title":"China's health system performance","volume":"372","author":"Liu","year":"2008","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1016\/s0140-6736(17)33109-4","article-title":"The primary health-care system in China","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/s0140-6736(17)32478-9","article-title":"Prevalence, awareness, treatment, and control of hypertension in China: data from 1\u00b77 million adults in a population-based screening study (China PEACE Million Persons Project)","volume":"390","author":"Lu","year":"2017","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1000333","DOI":"10.1371\/journal.pmed.1000333","article-title":"Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world","volume":"7","author":"Niens","year":"2010","journal-title":"PLoS Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e003698","DOI":"10.1136\/bmjopen-2013-003698","article-title":"Multidrug and optimal heart failure therapy prescribing in older general practice populations: a clinical data linkage study","volume":"4","author":"Rushton","year":"2014","journal-title":"BMJ Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jgs.15634","article-title":"Pharmacotherapy in older adults with cardiovascular disease: report from an American college of cardiology, American geriatrics society, and national Institute on aging workshop","volume":"67","author":"Schwartz","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/eurheartj\/ehm594","article-title":"Atrial fibrillation subtypes, risk of stroke, and antithrombotic therapy","volume":"29","author":"Stramba-Badiale","year":"2008","journal-title":"Eur. Heart J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1177\/2047487313487621","article-title":"Highly prevalent and poorly controlled cardiovascular risk factors among Chinese elderly people living in the rural community","volume":"21","author":"Song","year":"2014","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/ijerph14111391","article-title":"The trends in cardiovascular diseases and respiratory diseases mortality in urban and rural China, 1990\u20132015","volume":"14","author":"Sun","year":"2017","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1093\/eurheartj\/ehv428","article-title":"Cardiovascular disease in Europe\u2013epidemiological update 2015","volume":"36","author":"Townsend","year":"2015","journal-title":"Eur. Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ebiom.2017.06.017","article-title":"Effects of macronutrient distribution on weight and related cardiometabolic profile in healthy non-obese Chinese: a 6-month, randomized controlled-feeding trial","volume":"22","author":"Wan","year":"2017","journal-title":"EBioMedicine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2174\/1381612822666161010105242","article-title":"Salvia miltiorrhiza: a potential red light to the development of cardiovascular diseases","volume":"23","author":"Wang","year":"2017","journal-title":"Curr. Pharmaceut. Des."},{"key":"B39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jacl.2020.04.005","article-title":"Characterizing lipid profiles associated with asymptomatic intracranial arterial stenosis in rural-dwelling adults: a population-based study","volume":"14","author":"Wang","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1067\/mhj.2002.120965","article-title":"Cost and cost-effectiveness studies in heart failure research","volume":"143","author":"Weintraub","year":"2002","journal-title":"Am. Heart J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1747-4949.2011.00667.x","article-title":"Underuse of antithrombotic therapy caused high incidence of ischemic stroke in patients with atrial fibrillation","volume":"7","author":"Yu","year":"2012","journal-title":"Int. J. Stroke"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/s0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/hpm.2554","article-title":"Social health insurance vs private health insurance in China: revisit crowd-out effect based on a multiple mediation analysis","volume":"33","author":"Zhang","year":"2018","journal-title":"Int. J. Health Plann. Manag."},{"key":"B44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/s0140-6736(15)00551-6","article-title":"Cause-specific mortality for 240 causes in China during 1990\u20132013: a systematic subnational analysis for the Global Burden of Disease Study 2013","volume":"387","author":"Zhou","year":"2016","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.608136\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T06:07:48Z","timestamp":1608271668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.608136\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":44,"alternative-id":["10.3389\/fphar.2020.608136"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.608136","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"article-number":"608136"}}